PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting
19 Sep 2023
Radiation TherapyASCOClinical Study
PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting
Data to Address Limitations in the Applications of Clinicopathologic Factors
LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS). This comparison data was selected for a scientific session oral presentation at the 65th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 1-4, 2023 at the San Diego Convention Center, San Diego, CA.
“We are pleased to have our new comparison data on DCISionRT selected for oral presentation at the prestigious ASTRO Annual Meeting,” said Dan Forche, President and CEO of PreludeDx. “This new data is being presented by Dr. Frank A. Vicini, who will share how this data further validates the value of DCISionRT in guiding treatment decisions for DCIS patients.”
Oral Presentation
Title: Number 100: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology, and first author of the study
Date: Sunday, October 1, 8:00 AM PT
Location: Room 6B
Additional PreludeDx ASTRO Posters Will Be Presented
Title: Number 2439: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
Presenter: Chirag S. Shah, MD, Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer InstituteCancer Institute, Cleveland Clinic, Cleveland, OH
Date: Monday, October 2, 3:00 PM PT
Location: Hall B1
Title: Number 57473: A Biosignature Integrating Immune and Metabolic Signaling Axes to Assess Limited Radiation Therapy Response in Early-Stage Breast Cancer from a Low-Risk Cohort
Presenter: Troy Bremer, PhD, Chief Scientific Officer, PreludeDx
Date: Monday, October 2, 3:00 PM PT
Location: Hall B2
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer InstituteCancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score™ that identifies a woman’s risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT’s intelligent reporting provides a woman’s recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.
About PreludeDx
PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk™. PreludeDx is a Fjord Ventures portfolio company.
For more information on how PreludeDx is making a difference for patients, please visit the Company’s website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.
PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, DecisionTree, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.
Media Contact Investor Contact Cory Dunn Andrew Wade760.705.7464 949.600.8925 cdunn@preludedx.com awade@preludedx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d1b2a32-9654-4122-ac60-8838c4d3e42a
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.